Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1A | P54750 | 14/20 | 0.40 |
| ▸ | PDE1B | Q01064 | 14/20 | 0.40 |
| ▸ | PDE1C | Q14123 | 14/20 | 0.40 |
| ▸ | METAP2 | P50579 | 2/20 | 0.40 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28195540 | 0.84 | L3MBTL1 (0.47) | PDE1APDE1BPDE1CMETAP2L3MBTL1 | |
| SCHEMBL2037809 | 0.83 | BTK (0.46) | L3MBTL1ALOX5AP | |
| SCHEMBL2044328 | 0.83 | FFAR2 (0.41) | ALOX5AP | |
| SCHEMBL8214958 | 0.78 | ADRB2 (0.50) | PDE1APDE1BPDE1CMETAP2RORC | |
| SCHEMBL29982576 | 0.77 | PDE1A (0.45) | PDE1APDE1BPDE1CL3MBTL1HPGD | |
| SCHEMBL28944832 | 0.77 | ALDH1A1 (0.41) | PDE1APDE1BPDE1CL3MBTL1HPGD | |
| SCHEMBL29983324 | 0.77 | CYP19A1 (0.50) | PDE1APDE1BPDE1CHPGDSMN1; SMN2 | |
| SCHEMBL2006626 | 0.75 | PDE1A (0.43) | PDE1APDE1BPDE1CMETAP2ALOX5AP | |
| SCHEMBL5097231 | 0.74 | PDE1A (0.39) | PDE1APDE1BPDE1CL3MBTL1 | |
| SCHEMBL444326 | 0.74 | PTPRC (0.51) | L3MBTL1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7452880-B2 | Substituted pyrazolo [3,4-d] pyrimidines and methods of using the same | F. HOFFMANN-LA ROCHE AG (CH) | 2008-11-18 | — | — | US | claimed |
| US-20050203091-A1 | Heteroaryl-fused pyrazolo derivatives and methods for using the same | ROCHE PALO ALTO LLC | 2005-09-15 | — | — | US | claimed |
| US-7452880-B2 | Substituted pyrazolo [3,4-d] pyrimidines and methods of using the same | F. HOFFMANN-LA ROCHE AG (CH) | 2008-11-18 | — | — | US | disclosed |
| EP-1720878-A1 | HETEROARYL-FUSED PYRAZOLO DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-11-15 | — | — | EP | disclosed |
| US-20050203091-A1 | Heteroaryl-fused pyrazolo derivatives and methods for using the same | ROCHE PALO ALTO LLC | 2005-09-15 | — | — | US | disclosed |
| WO-2005085248-A1 | HETEROARYL-FUSED PYRAZOLO DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2005-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203091-A1 | Heteroaryl-fused pyrazolo derivatives and methods for using the same | MAP3K1, MAP3K21, MAP3K2 | PDE1A 845/4885PDE1B 715/4885PDE1C 1405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.